YUAN, SHENGTAO

Release date:2016-05-25  Release:

YUAN, SHENGTAO

Professor of pharmacology

Phone: 86-25-83271043

Email: 13914798635@163.com

Research Summary

Cancer is the leading cause of human death. However, today’s cancer therapy usually fails to increase the survival of patients because of severe toxic side effects, recurrence or metastasis. My concerns focus on the tumor microenvironment, which is the soil of cancer initiation and progression. Targeting tumor microenvironment can inhibit cancer cell migration, block cancer nutrition supply, and increase drug sensitivity. We also do drug screening for novel anti-cancer candidates without severe toxic side effects. DT-13, one potent NM-IIA inhibitor that selectively inhibits cancer metastasis, is now in the stage of preclinical study. Our research data were published on decent cancer journals like Oncotarget, Cancer Lett, Oncogene and Cancer Sci.

Education

INSTITUTION

DEGREE

YEAR(s)

FIELD OF STUDY

Jiangxi Medical College, Nanchang, China


B.S.

1986-1990

Medical Science

Shanghai Medical University, Shanghai, China

M.S.

1993-1996

Pathology

Shanghai Institute of Materia Medica, Shanghai, China

Ph.D.

1998-2001

Pharmacology


Positions and Employment

    1. Research assistant, Jiangxi Medical College, Nanchang, China

1996-2003   Research assistant, Shanghai Institute of Materia Medica, Shanghai, China

2004-present    Research assistant/Associate Research Fellow, China Pharmaceutical University, Nanjing, China

Peer-reviewed publications

  1. Yu XW, Lin S, Du HZ, Zhao RP, Feng SY, Yu BY, Zhang LY, Li RM, Qian CM, Luo XJ, Yuan ST, Sun L. Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of egf receptor in vitro and in vivo. Oncotarget. 2016 Apr 20. doi: 10.18632/oncotarget.8843. [Epub ahead of print]

  2. Li H, Sun L, de Carvalho EL, Li X, Lv X, Khan GJ, Semukunzi H, Yuan S, Lin S. DT-13, a saponin monomer of dwarf lilyturf tuber, induces autophagy and potentiates anti-cancer effect of nutrient deprivation. Eur J Pharmacol. 2016; 781: 164-72.

  3. Sun L, Liu Y, Lin S, Shang J, Liu J, Li J, Yuan S, Zhang L. Early growth response gene-1 and hypoxia-inducible factor-1α affect tumor metastasis via regulation of tissue factor. Acta Oncol. 2013; 52(4):842-51. (IF 3.33)

  4. Zhao R, Sun L, Lin S, Bai X, Yu B, Yuan S, Zhang L. The saponin monomer of dwarf lilyturf tuber, DT-13, inhibits angiogenesis under hypoxia and normoxia via multi-targeting activity. Oncol Rep. 2013; 29(4): 1379-86.

  5. Fang D, Sun L, Lin S, Zhou L, Su N, Yuan S, Yu B. Vinorelbine inhibits angiogenesis and 95D migration via reducing hypoxic fibroblast stromal cell-derived factor 1 secretion. Exp Biol Med. 2012; 237(9): 1045-55.

  6. Zhu J, Sun L, Lin S, Zhao R, Zhou L, Fang D, Chen L, Liu J, Shi W, Zhang L, Yuan S. BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells. J Exp Clin Cancer Res. 2012; 31: 31.

  7. Lin SS, Wan SY, Sun L, Hu JL, Fang DD, Zhao RP, Yuan ST, Zhang LY. Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Sci. 2012; 103(5): 904-12.

  8. Jiang W, Kou J, Yuan S, Sun L, Yu B. A simplified and high-throughput chromogenic assay for testing tissue factor-dependent procoagulant activity. J Biomol Screen. 2011; 16(3): 295-302.

  9. Sun L, Lin S, Zhao R, Yu B, Yuan S, Zhang L. The saponin monomer of dwarf   lilyturf tuber, DT-13, reduces human breast cancer cell adhesion and migration during hypoxia via regulation of tissue factor. Biol Pharm Bull. 2010; 33(7): 1192-8.

  10. Huang Z, Zhang Y, Zhao L, Jing Y, Lai Y, Zhang L, Guo Q, Yuan S, Zhang J, Chen L, Peng S, Tian J. Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid. Org Biomol Chem. 2010; 8(3): 632-9.

  11. Zhou L, Sun L, Lin S, Fang D, Zhao R, Zhu J, Liu J, Chen L, Shi W, Yuan S, Zhu D. Inhibition of angiogenic activity of hypoxic fibroblast cell line MRC-5 in vitro by topotecan. Med Oncol. 2010 Nov 9.

  12. Lin S, Sun L, Hu J, Wan S, Zhao R, Yuan S, Zhang L. Chemokine C-X-C motif receptor 6 contributes to cell migration during hypoxia. Cancer Lett. 2009; 279(1): 108-17.

  13. Lin SS, Sun L, Zhang YK, Zhao RP, Liang WL, Yuan ST, Zhang LY. Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases. Acta Pharmacol Sin. 2009; 30(5): 628-36.

  14. Xu J, Yang J, Ran Q, Wang L, Liu J, Wang Z, Wu X, Hua W, Yuan S, Zhang L, Shen M, Ding Y. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates. Bioorg Med Chem Lett 2008; 18(16): 4741-4.

  15. Zhang C, Qu G, Sun Y, Wu X, Yao Z, Guo Q, Ding Q, Yuan S, Shen Z, Ping Q, Zhou H. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials 2008; 29(9): 1233-41.